Protocol Ledger

NCT06772168 · Phase III · RECRUITING

Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

Interventional Phase III clinical trial protocol NCT06772168 sponsored by CMG Pharmaceutical Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-19 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06772168
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06772168
Protocol FieldVerified Registry Value
NCT IdentifierNCT06772168
Consolidated Lead SponsorCMG Pharmaceutical Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2024-04-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06772168
Hospital Research SiteLocationSite Profile
Seoul National University Bundang HospitalSeongnam, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI